# A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

> **NCT05699239** · PHASE2 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 326 (actual)

## Conditions studied

- Hyperphosphatemia Patients on Hemodialysis

## Interventions

- **DRUG:** TS-172 10mg bid
- **DRUG:** TS-172 30mg bid
- **DRUG:** TS-172 60mg bid
- **DRUG:** TS-172 20mg tid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05699239
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-08
- **Primary completion:** 2023-12-26
- **Final completion:** 2023-12-26
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699239, "A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05699239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*